1.
Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica [Internet]. 2009Feb.27 [cited 2026Nov.16];94(3):433-5. Available from: https://haematologica.org/article/view/5208